RxDoctor Payments Data

Kathleen Cizek, MD

Internal Medicine · Saint Louis, MONPI 1083605331

Payments from drug & device makers

$3,859in general payments, 2019–2025

Across 214 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$830
  • Pfizer$444
  • Novo Nordisk$299
  • Lilly USA, LLC$283
  • AstraZeneca$265
  • Amgen$263
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,77498%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,859 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$120,268
Medicare patients
181
Services billed
2,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$162,238
OzempicSemaglutide120$127,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$48,766
FarxigaDapagliflozin Propanediol64$43,731
ProliaDenosumab22$36,336
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$26,704
MounjaroTirzepatide13$26,413
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$22,844
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog34$22,507
TrulicityDulaglutide15$17,925
MyrbetriqMirabegron34$17,543
Breo ElliptaFluticasone/Vilanterol33$16,129
Mirabegron ErMirabegron32$15,133
Semglee (Yfgn) PenInsulin Glargine-Yfgn32$13,946
Spiriva RespimatTiotropium Bromide17$13,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$444$162,238210 claims
Novo NordiskOzempic$299$127,012120 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy$184$96,665156 claims
Lilly USA, LLCMounjaro, Trulicity$283$44,33828 claims
AstraZenecaFarxiga$265$43,73164 claims
AmgenProlia$263$36,33622 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$110$19,21330 claims
Astellas Pharma US IncMyrbetriq$198$17,54334 claims
Johnson & JohnsonXarelto$146$11,72111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →